|Table of Contents|

Expression and clinical significance of EBP50 and EGFR in clear cell renal cell carcinoma

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2024 06
Page:
1101-1105
Research Field:
Publishing date:

Info

Title:
Expression and clinical significance of EBP50 and EGFR in clear cell renal cell carcinoma
Author(s):
XIAO Xuelan1; WANG Xiaomei1; WU Liping2; MA Jianguo3; SUN Hongjing1; HAO Suhui1; GAO Feng1
1.Department of Pathology,the Third Hospital of Hebei Medical University,Hebei Shijiazhuang 050051,China;2.Department of Pathology,Daping Hospital,Army Medical University,Chongqing 400042,China;3.Department of Urology,the Third Hospital of Hebei Medical University,Hebei Shijiazhuang 050051,China.
Keywords:
clear cell renal cell carcinoma; ERM-binding phosphoprotein-50; epidermal growth factor receptor; correlation
PACS:
R737.11
DOI:
10.3969/j.issn.1672-4992.2024.06.020
Abstract:
Objective:To investigate the expression and correlation of EBP50 and EGFR in clear cell renal cell carcinoma and normal renal tissues,and to analyze the relationship between EBP50 and EGFR and clinicopathological features of patients.Methods:The expression of EBP50 and EGFR in primary ccRCC,metastatic ccRCC and normal renal tissues were detected by immunohistochemistry.The correlation between EBP50 and EGFR and the clinicopathological features of ccRCC were also examined in primary ccRCC.Results:The positive expression rate of EBP50 in primary and metastatic ccRCC was lower than that in normal renal tissues,while the positive expression rate of EGFR in primary and metastatic ccRCC was higher than that in normal renal tissues.In primary ccRCC,the expression of EBP50 was significantly different in age and Fuhrman,and the expression of EGFR was significantly different in the largest diameter of tumor and Fuhrman.The expression of EBP50 was inversely correlated with EGFR in primary ccRCC.Conclusion:In ccRCC,EBP50 expression is low and EGFR expression is high.EBP50 may act as a tumor suppressor and EGFR may be carcinogenic.EBP50 may play an anti-tumor role by inhibiting the expression and function of EGFR.EBP50 and EGFR can help pathologists to judge the grade of ccRCC.

References:

［1］ 崔帆,双卫兵.肾癌与血脂相关性研究进展［J］.现代肿瘤医学,2023,31(19):3707-3710. CUI F,SHUANG WB.Research progress of relationship between renal cell carcinoma and blood lipid ［J］.Modern Oncology,2023,31(19):3707-3710.
［2］ OHSUGI H,YOSHIDA T,OHE C,et al.The SSPN score,a novel scoring system incorporating PBRM1 expression,predicts postoperative recurrence for patients with non-metastatic clear cell renal cell carcinoma ［J］.Annals of Surgical Oncology,2021,28(4):2359-2366.
［3］ DONG D,MU Z,WEI N,et al.Long non-coding RNA ZFAS1 promotes proliferation and metastasis of clear cell renal cell carcinoma via targeting miR-10a/SKA1 pathway ［J］.Biomedicine & Pharmacotherapy,2019,111:917-925.
［4］ PADALA SA,BARSOUK A,THANDRA KC,et al.Epidemiology of renal cell carcinoma ［J］.World Journal of Oncology,2020,11(3):79-87.
［5］ BELLIZZI A,MALFETTONE A,CARDONE RA,et al.NHERF1/EBP50 in breast cancer:clinical perspectives ［J］.Breast Care (Basel,Switzerland),2010,5(2):86-90.
［6］ MATSUMOTO T,YOKI A,KONNO R,et al.Cytoplasmic EBP50 and elevated PARP1 are unfavorable prognostic factors in ovarian clear cell carcinoma ［J］.Carcinogenesis,2021,42(9):1162-1170.
［7］ GRECO MR,BON E,RUBINO R,et al.Phosphorylation of NHERF1 S279 and S301 differentially regulates breast cancer cell phenotype and metastatic organotropism ［J］.Biochimica et Biophysica Acta Molecular Basis of Disease,2019,1865(1):26-37.
［8］ 马好霞,李进磊,王丽雁.TKI治疗EGFR基因突变非小细胞肺癌患者疗效与PD-L1表达的关系［J］.国际检验医学杂志,2023,44(17):2117-2121，2128. MA HX,LI JL,WANG LY.Relationship between the efficacy of TKI therapy and the expression of PD-L1 in patients with EGFR-mutant non-small cell lung cancer ［J］.Int J Lab Med,2023,44(17):2117-2121，2128.
［9］ 蔡仁中,李高,蔡用清.EBP50和EGFR在食管癌中的表达和临床意义［J］.基因组学与应用生物学,2018,37(12):5544-5551. CAI RZ,LI G,CAI YQ.Expressions and clinical significance of EBP50 and EGFR in esophageal carcinoma［J］.Genomics and Applied Biology,2018,37(12):5544-5551.
［10］ YAO W,FENG D,BIAN W,et al.EBP50 inhibits EGF-induced breast cancer cell proliferation by blocking EGFR phosphorylation ［J］.Amino Acids,2012,43(5):2027-2035.
［11］ PENG Z,WANG Q,ZHANG Y,et al.EBP50 interacts with EGFR and regulates EGFR signaling to affect the prognosis of cervical cancer patients ［J］.International Journal of Oncology,2016,49(4):1737-1745.
［12］ CLAPRON A,GUEDJ N,MERGEY M,et al.Loss of EBP50 stimulates EGFR activity to induce EMT phenotypic features in biliary cancer cells ［J］.Oncogene,2012,31(11):1376-1388.
［13］ 孟贵卿,李芳,殷凤朝.E2F-3、E2F-4蛋白在透明细胞性肾细胞癌中的表达及临床意义［J］.诊断病理学杂志,2022,29(01):31-36. MENG GQ,LI F,YIN FC.Expression of E2F-4 proteins in clear cell carcinoma and their clinical significance ［J］.Chinese Journal of Diagnostic Pathology,2022,29(01):31-36.
［14］ 孙涛.肾透明细胞癌中Claudin-8的表达及其意义［D］.沈阳：中国医科大学,2021. SUN T.Expression and significance of Claudin-8 in clear cell renal cell carcinoma ［D］.Shenyang:China Medical University,2021.
［15］ 孙巍.Ki67和TGF-β1在肾透明细胞癌中的表达及相关性研究［D］.蚌埠:蚌埠医学院,2015. SUN W.Study on expression of Ki67 and TGF-β1 in clear cellrenal cell carcinoma and their relationships ［D］.Bengbu:Bengbu Medical College,2015.
［16］ 陈海滨,王立姣,赵鹏,等.EPAS-1在透明细胞性肾细胞癌中的表达及意义［J］.西部医学,2022,34(02):235-239,244. CHEN HB,WANG LJ,ZHAO P,et al.Expression and significance of EPAS-1 in clear cell renal cell carcinoma［J］.Med J West China,2022,34(02):235-239,244.
［17］ 陈土明,洪新凯,吴超群,等.结肠癌组织中的β-catenin和EBP50表达与肿瘤发生的关系［J］.黑龙江中医药,2019,48(01):143-145. CHEN SM,HONG XK,WU CQ,et al.Relationship between β-catenin and EBP50 expression and tumorigenesis in colon cancer tissues ［J］.Heilongjiang Journal of Traditional Chinese Medicine,2019,48(01):143-145.
［18］ 雷坤阳,谢文杰,孙庭,等.长链非编码RNA ARAP1-AS1在肾透明细胞癌中的表达及作用研究［J］.中国癌症杂志,2022,32(01):34-40. LEI KY,XIE WJ,SUN T,et al.Expression and effect of long non-coding RNA ARAP1-AS1 in clear cell renal cell carcinoma ［J］.China Oncology,2022,32(01):34-40.
［19］ LANG YD,JOU YS.PSPC1 is a new contextual determinant of aberrant subcellular translocation of oncogenes in tumor progression ［J］.Journal of Biomedical Science,2021,28(1):57.
［20］ BROADBENT D,AHMADZAI MM,KAMMALA AK,et al.Roles of NHERF family of PDZ-binding proteins in regulating GPCR functions ［J］.Advances in Immunology,2017,136:353-385.
［21］ KAWASE A,HIROSOKO M,SUGIHARA Y,et al.NHERF1/EBP50 as a target for modulation of MRP function in HepG2 cells ［J］.Pharmaceuticals (Basel,Switzerland),2021,14(3):239.
［22］ ZHANG W,JIANG Y,YU Q,et al.EGFR promoter methylation,EGFR mutation,and HPV infection in Chinese cervical squamous cell carcinoma ［J］.Applied Immunohistochemistry & Molecular Morphology,2015,23(9):661-666.
［23］ FIORENTINO M,GRUPPIONI E,MASSARI F,et al.Wide spetcrum mutational analysis of metastatic renal cell cancer:a retrospective next generation sequencing approach ［J］.Oncotarget,2017,8(5):7328-7335.
［24］ ZHENG JF,SUN LC,LIU H,et al.EBP50 exerts tumor suppressor activity by promoting cell apoptosis and retarding extracellular signal-regulated kinase activity ［J］.Amino Acids,2010,38(4):1261-1268.

Memo

Memo:
河北省医学科学研究重点项目（编号：20230668）
Last Update: 1900-01-01